Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)
South Korea
· Delayed Price · Currency is KRW 8,820.00
-90.00 (-1.01%)
Jun 27, 2025, 3:30 PM KST
Hyundai Bioscience Revenue
Hyundai Bioscience had revenue of 708.79M KRW in the quarter ending March 31, 2025, a decrease of -85.96%. This brings the company's revenue in the last twelve months to 10.71B, down -5.80% year-over-year. In the year 2024, Hyundai Bioscience had annual revenue of 15.05B with 58.73% growth.
Revenue (ttm)
10.71B
Revenue Growth
-5.80%
P/S Ratio
45.02
Revenue / Employee
198.32M
Employees
54
Market Cap
482.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 15.05B | 5.57B | 58.73% |
| Dec 31, 2023 | 9.48B | 1.63B | 20.76% |
| Dec 31, 2022 | 7.85B | -1.39B | -15.04% |
| Dec 31, 2021 | 9.24B | -3.27B | -26.14% |
| Dec 31, 2020 | 12.51B | -17.57B | -58.41% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,898.69B |
| Celltrion | 3,662.23B |
| ALTEOGEN | 151.65B |
| Yuhan | 2,114.76B |
| SK Biopharmaceuticals | 578.00B |
| HLB Co., Ltd. | 74.64B |
| PharmaResearch | 392.31B |
| Peptron | 4.30B |